Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-10-28 03:49Group 1 - The core point of the article highlights the recent decline in the stock price of Jiangsu Hengrui Medicine Co., Ltd., which fell by 5.13% to 63.57 CNY per share, with a total market capitalization of 421.93 billion CNY [1] - Jiangsu Hengrui Medicine, established on April 28, 1997, and listed on October 18, 2000, focuses on the research, production, and sales of pharmaceuticals, particularly in the oncology field, covering various therapeutic areas including kinase inhibitors, antibody-drug conjugates (ADC), and immunotherapy [1] - The company's main revenue sources are product sales (86.88%), licensing income (12.63%), and other income (0.49%), indicating a strong focus on product sales [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Securities Asset Management has Hengrui Medicine as a significant holding, with 362,000 shares representing 3.27% of the fund's net value, ranking as the ninth largest holding [2] - The fund, Caitong Asset Management Chenrui One-Year Holding Period Mixed A (010413), has a current scale of 5.09 billion CNY and has achieved a year-to-date return of 28.4%, ranking 3444 out of 8155 in its category [2] - The fund manager, Li Xiang, has been in position for over 7 years, with the best fund return during his tenure being 37.6% and the worst being -30.26% [3]